Vasantha Jotwani, MD

Headshot of Vasantha Jotwani
User Profile Photo

Vasantha Jotwani, MD

User Profile Name
Associate Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

I am a clinician-investigator at UCSF and the San Francisco VA Medical Center, and my goal is to reduce the burden of kidney disease by identifying and intervening on kidney injury at the earliest stages. I am the recipient of a NHLBI-funded R01 to investigate the intersection of mitochondrial health, cardiovascular risk and blood pressure targets in hypertensive adults, and a NIDDK-funded K23 award focused on urinary biomarkers for detection of drug-induced nephrotoxicity in persons with and without HIV infection. My initial work demonstrated the potential for urinary biomarkers to capture distinct types of kidney damage and to prognosticate long-term kidney risk in HIV-infected individuals. With our collaborators, we built a panel of urinary biomarkers to detect kidney damage across the nephron; these markers have been studied in various settings as indicators of acute kidney injury and chronic kidney disease. My work made the novel contribution that biomarkers specific for tubular dysfunction and injury can be used to identify tubular toxicity from antiretroviral medications, both in HIV-infected individuals and in HIV-uninfected individuals receiving pre-exposure prophylaxis. Additionally, I am a co-Investigator for an ongoing NIDDK-funded R01 that focuses on urinary biomarkers of kidney tubular health in SPRINT participants with CKD. I also serve as a co-Investigator for a NIA-funded R01 that aims to investigate the role of mitochondrial health in acute and chronic kidney diseases and a NIDDK-funded R01 that will examine the impact of mitochondrial health on kidney function in an exercise trial. 

I am dedicated to my clinical practice as a nephrologist, and I care for patients at the San Francisco VA Medical Center (SFVAMC) and UCSF Parnassus Medical Center. At the SFVAMC, I serve on the inpatient nephrology consult service and I provide outpatient nephrology consultation services for referring physicians through the SFVA Renal clinic. I also provide outpatient nephrology consultation services through the UCSF Parnassus Nephrology practice, where I have held an ambulatory panel since 2014. I manage a small dialysis practice at Satellite Health and Wellbound for my patients who have progressed to end-stage kidney disease. 

Finally, I serve as the SFVAMC Site Director for the UCSF Nephrology Fellowship program. In this capacity, I oversee the nephrology fellows on all clinical, elective and research rotations at the SFVAMC. I am responsible for design, organization, and implementation of the weekly fellowship lecture series, and I chair the Nephrology Fellowship Program Evaluation Committee. In July of 2021, we launched a wellness program for the UCSF Nephrology Fellowship program. Developed with input from fellows and with the support of division leadership, our multi-pronged program includes social events to improve fellows' sense of connection, monthly tips that address health and well-being, and monthly recognition of 2-3 fellows to appreciate their efforts.

User Profile Bio

Displaying 26 - 42 of 42

  1. Jotwani V, Katz R, Ix JH, Guti?rrez OM, Bennett M, Parikh CR, Cummings SR, Sarnak MJ, Shlipak MG. Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders. Am J Kidney Dis. 2018 08; 72(2):205-213.
  2. Jotwani V, Atta MG, Estrella MM. Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. J Am Soc Nephrol. 2017 Nov; 28(11):3142-3154.
  3. Ix JH, Jotwani V, Shlipak MG. In Reply to 'Urinary Excretion of a1-Microglobulin Does Not Predict Graft Loss in Stable Kidney Transplant Recipients'. Am J Kidney Dis. 2017 07; 70(1):151-152.
  4. Park M, Katz R, Shlipak MG, Weiner D, Tracy R, Jotwani V, Hughes-Austin J, Gabbai F, Hsu CY, Pfeffer M, Bansal N, Bostom A, Gutierrez O, Sarnak M, Levey A, Ix JH. Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial. Am J Transplant. 2017 Oct; 17(10):2640-2649.
  5. Chen R, Scherzer R, Hsue PY, Jotwani V, Estrella MM, Horberg MA, Grunfeld C, Shlipak MG. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc. 2017 Apr 24; 6(4).
  6. Baxi SM, Scherzer R, Jotwani V, Estrella MM, Abraham AG, Parikh CR, Bennett MR, Cohen MH, Nowicki MJ, Gustafson DR, Sharma A, Young MA, Shlipak MG, Women's Interagency HIV Study (WIHS). Changes in Urinary Biomarkers Over 10 Years Is Associated With Viral Suppression in a Prospective Cohort of Women Living With HIV. J Acquir Immune Defic Syndr. 2017 Apr 15; 74(5):e138-e145.
  7. Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella F, Ho K, Bennett M, Parikh CR, Ix JH, Shlipak M. Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study. Antivir Ther. 2017; 22(5):421-429.
  8. Ix JH, Katz R, Bansal N, Foster M, Weiner DE, Tracy R, Jotwani V, Hughes-Austin J, McKay D, Gabbai F, Hsu CY, Bostom A, Levey AS, Shlipak MG. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. Am J Kidney Dis. 2017 Mar; 69(3):410-419.
  9. Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella F, Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak M. Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):177-81.
  10. Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella FJ, Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak MG. HIV Infection, Tenofovir, and Urine a1-Microglobulin: A�Cross-sectional Analysis in the Multicenter AIDS Cohort Study. Am J Kidney Dis. 2016 Oct; 68(4):571-581.
  11. Imp BM, Rubin LH, Tien PC, Plankey MW, Golub ET, French AL, Valcour VG. Monocyte Activation Is Associated With Worse Cognitive Performance in HIV-Infected Women With Virologic Suppression. J Infect Dis. 2017 Jan 01; 215(1):114-121.
  12. Lyndsey Hornbuckle, C. Christina Mehta, Phyllis Tien, David Hanna, Jason Lazar, Lorie Benning, Mardge Cohen, Wendy Mack, Michael Plankey, Gina Wingood. Relationship Between Physical Activity And Cardiovascular Disease Risk In The Women’s Interagency HIV Study. Medicine & Science in Sports & Exercise. 2016 May 1; 48(5S):227.
  13. Sharma A, Hoover DR, Shi Q, Gustafson D, Plankey MW, Hershow RC, Tien PC, Golub ET, Anastos K. Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study. PLoS One. 2015; 10(12):e0143740.
  14. Frasco MA, Karim R, Van Den Berg D, Watanabe RM, Anastos K, Cohen M, Gange SJ, Gustafson DR, Liu C, Tien PC, Mack WJ, Pearce CL. Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women. AIDS. 2014 Jul 31; 28(12):1815-23.
  15. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis. 2012 May; 59(5):628-35.
  16. Jotwani V, Scherzer R, Choi A, Szczech L, Polak JF, Kronmal RA, Grunfeld C, Shlipak M. Reduced kidney function and preclinical atherosclerosis in HIV-infected individuals: the study of fat redistribution and metabolic change in HIV infection (FRAM). Am J Nephrol. 2011; 33(5):453-60.
  17. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008 Mar; 57(3):714-23.